Drug Profile
Research programme: siRNA kidney disorder therapeutics - Quark Pharmaceuticals
Alternative Names: PFTiLatest Information Update: 06 Sep 2010
Price :
$50
*
At a glance
- Originator Quark Biotech
- Developer Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Renal failure
Most Recent Events
- 06 Sep 2010 No development reported - Preclinical for Renal failure in USA (IV)
- 14 Oct 2008 Preclinical development is ongoing in USA
- 19 Dec 2006 Preclinical trials in Renal failure in USA (Injection)